Prognostic significance of VNN2 expression in a multivariable setting (n = 476)
| Group . | HR . | LL . | UL . | P (χ2) . |
|---|---|---|---|---|
| Cox EFS | ||||
| MRD HR | 5.16 | 2.58 | 10.32 | <.001 |
| VNN2 | 2.14 | 1.28 | 3.55 | .003 |
| SET | 2.67 | 1.19 | 6.00 | .017 |
| WBC ≥100 000 | 2.01 | 1.08 | 3.73 | .027 |
| MRD SR | 0.74 | 0.43 | 1.27 | .275 |
| Pred. resp. | 0.71 | 0.33 | 1.52 | .379 |
| ETV6-RUNX1 | 0.93 | 0.51 | 1.70 | .812 |
| Cox RFS | ||||
| VNN2 | 1.97 | 1.13 | 3.44 | .016 |
| MRD HR | 2.85 | 1.20 | 6.80 | .018 |
| WBC ≥100 000 | 2.17 | 1.12 | 4.21 | .021 |
| SER | 2.41 | 1.01 | 5.74 | .046 |
| MRD SR | 0.67 | 0.37 | 1.21 | .182 |
| ETV6-RUNX1 | 0.74 | 0.38 | 1.45 | .379 |
| Pred. resp. | 0.81 | 0.35 | 1.86 | .623 |
| Group . | HR . | LL . | UL . | P (χ2) . |
|---|---|---|---|---|
| Cox EFS | ||||
| MRD HR | 5.16 | 2.58 | 10.32 | <.001 |
| VNN2 | 2.14 | 1.28 | 3.55 | .003 |
| SET | 2.67 | 1.19 | 6.00 | .017 |
| WBC ≥100 000 | 2.01 | 1.08 | 3.73 | .027 |
| MRD SR | 0.74 | 0.43 | 1.27 | .275 |
| Pred. resp. | 0.71 | 0.33 | 1.52 | .379 |
| ETV6-RUNX1 | 0.93 | 0.51 | 1.70 | .812 |
| Cox RFS | ||||
| VNN2 | 1.97 | 1.13 | 3.44 | .016 |
| MRD HR | 2.85 | 1.20 | 6.80 | .018 |
| WBC ≥100 000 | 2.17 | 1.12 | 4.21 | .021 |
| SER | 2.41 | 1.01 | 5.74 | .046 |
| MRD SR | 0.67 | 0.37 | 1.21 | .182 |
| ETV6-RUNX1 | 0.74 | 0.38 | 1.45 | .379 |
| Pred. resp. | 0.81 | 0.35 | 1.86 | .623 |
Analysis was performed on 476 samples from the test set from ALL-BFM 2000.
EFS, event-free survival; HR, hazard ratio; LL, lower limit of 95% confidence interval; Pred. resp, prednisone good responders; RFS, relapse-free survival; SER, slow early responders, a HR criterium; UL, upper limit of 95% confidence interval; WBC, white blood cell.